Storia in 3 fonti

First Oral Option for Dermatomyositis Gets FDA Green Light

Brepocitinib significantly improved overall symptom status in a phase III trial

Raccontata da

healio.com

medpagetoday.com

biopharmadive.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo2 g fa

First Oral Option for Dermatomyositis Gets FDA Green Light

Brepocitinib significantly improved overall symptom status in a phase III trial

originale

healio.com2 g fa

FDA approves Lisraya as first oral drug for dermatomyositis

The FDA has approved Lisraya for the treatment of dermatomyositis in adults, the agency announced in a press release. The approval makes brepocitinib (Lisraya, Priovant Therapeutics) the first oral drug indicated for…

Leggi questa versione → originale

Timeline cronologica

mercoledì 26 agosto 2026·healio.com
Brepocitinib yields ‘consistent’ improvements in cutaneous dermatomyositis
Brepocitinib improved skin-specific symptoms of dermatomyositis, according to an analysis of the phase 3 VALOR trial published in JAMA Dermatology. These findings, which included…
giovedì 27 agosto 2026·medpagetoday.com
First Oral Option for Dermatomyositis Gets FDA Green Light
Brepocitinib significantly improved overall symptom status in a phase III trial

First Oral Option for Dermatomyositis Gets FDA Green Light

Confronto fonti

First Oral Option for Dermatomyositis Gets FDA Green Light

FDA approves Lisraya as first oral drug for dermatomyositis

Timeline cronologica

Brepocitinib yields ‘consistent’ improvements in cutaneous dermatomyositis

First Oral Option for Dermatomyositis Gets FDA Green Light

FDA green lights Priovant drug for rare skin disease

FDA approves Lisraya as first oral drug for dermatomyositis

FDA green lights Priovant drug for rare skin disease